The single injection viscosupplementation segment in the Russia viscosupplementation market is expected to expand at the fastest and highest CAGR of 6.0% over the forecast period, due to relatively less competition across the product type segments. The three injection viscosupplementation product type segment was estimated to account for more than 69.4% share of the Russia viscosupplementation market in 2016, which is projected to increase to over 68.8% by the end of 2026.
In Russia, three injection viscosupplementation is likely to be the highly preferred treatment of choice for osteoarthritis over the projected period and this is the precise reason that by the end of 2026, the three injection viscosupplementation product type segment is estimated to reach a market valuation in excess of US$ 23.5Mn. The three injection viscosupplementation product type segment is projected to be the most attractive segment in the Russia viscosupplementation market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Viscosupplemets are hyaluronic acid doses that are injected in the knee joints for the treatment of osteoarthritis (OA). The rising obesity rate, coupled with a rapidly increasing geriatric population in Russia is giving rise to an increasing number of cases of knee osteoarthritis. This factor is driving the growth of the single injection viscosupplementation segment in the Russia viscosupplementation market.
Increasing ageing population is another factor that is creating robust development in the Russia viscosupplementation market. Prevalence of osteoarthritis in the adult population in Russia is approximately 13%. Knee osteoarthritis is causing disability in the ageing population in Russia and this is the precise reason for the rise in demand for three injection viscosupplementation.
Three injection viscosupplementation is a cost-effective procedure that reduces the cost burden of knee osteoarthritis patients. Several drugs for three injection viscosupplementation are in the pipeline and this is further creating a positive impact on this segment. Better patient compliance and reduction in the number of hospital visits is expected to drive the market growth of the three injection viscosupplementation segment over the forecast period.
The cost of single injection viscosupplementation is lesser than three injection viscosupplementation. Besides, these three injections are available through online portals or can be procured directly from the pharmacists as well. However, several insurance companies and authorities do not consider these in the reimbursement list of products. Physicians have noted that the formulation of updated treatment guidelines by Osteoarthritis Research Society International (OARSI) for knee osteoarthritis has been restricting the overall outlook on viscosupplementation prescription.
This is expected to lead to increased insurance denials for three injection viscosupplementation. Three injection viscosupplementation is a lengthy procedure wherein patients suffering from osteoarthritis need to take three injections within the span of a certain time period. Owing to these restraints, single injections are expected to gain more popularity in Russia in the years to come.
Principal Consultant
The Russia viscosupplementation market is highly fragmented. Key players such as Hyaltech, Croma-Pharma GmbH and TRB Chemedica contribute around 65% of the market share. Hyaltech alone grabs more than 40% market share.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Demand for Russia viscosupplementation is likely to grow at a CAGR of 6.2% through 2032.
Sales of Russia viscosupplementation is likely to exceed a valuation of US$ 84.86 million by 2032.
Adoption of Russia viscosupplementation is likely to reach a valuation of US$ 46.5 million in 2022.
Rising obesity and ageing population are driving the growth of Russia viscosupplementation market.
1. Executive Summary
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. Global Russia Viscosupplementation Market Analysis Scenario
3.1. Pricing Analysis and Projection
3.2. Market Size (US$ Mn) and Forecast , 2015-2026
3.2.1. Market Size and Y-o-Y Growth
3.2.2. Absolute $ Opportunity
3.3. Market Overview
3.3.1. Value Chain
4. Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Forecast Factors – Relevance and Impact
4.6. Key Regulations
4.7. Pipeline Product Assessment
4.8. Pricing and Reimbursement Scenario
5. Russia Viscosupplementation Market Value and Volume Analysis and Forecasts, By Product Type
5.1. Introduction
5.2. Basis Point Share (BPS) Analysis By Product Type
5.3. Y-o-Y Growth Projections By Product Type
5.4. Market Value Forecast By Product Type , 2016–2026
5.4.1. Single Injection Viscosupplementation
5.4.2. Three Injection Viscosupplementation
5.4.3. Five Injection Viscosupplementation
5.5. Prominent Trends
5.6. Market Attractiveness By Product Type
6. Russia Viscosupplementation Market Value and Volume Analysis and Forecasts, By End User
6.1. Introduction
6.2. Basis Point Share (BPS) Analysis By End User
6.3. Y-o-Y Growth Projections By End User
6.4. Market Value Forecast By End User , 2016–2026
6.4.1. Hospitals
6.4.1.1. 500+ Beds
6.4.1.2. 250-499 Beds
6.4.1.3. Less than 250 Beds
6.4.2. Ambulatory Surgical Centers
6.4.3. Orthopedic Clinics
6.5. Prominent Trends
6.6. Market Attractiveness By End User
7. Competition Landscape
7.1.Competition Dashboard
7.2. Company Share Analysis (2015)
7.3.Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
7.3.1. Anika Therapeutics Inc.
7.3.2. Bioventus LLC
7.3.3. Ferring B.V
7.3.4. Fidia Pharmaceutici S.p.A
7.3.5. MEDA Pharmaceuticals Switzerland GmbH
7.3.6. Sanofi S.A
7.3.7. ZIMMER BIOMET HOLDINGS, INC
8. Assumptions and Acronyms Used
9. Research Methodology
Explore Healthcare Insights
View Reports
Russia Viscosupplementation Market
